Prediction of recurrence from metabolites and expression of TOP2A and EZH2 in prostate cancer patients treated with radiotherapy.
Ailin Falkmo HansenTherese Stork HøiemKirsten Margrete SelnaesAnna Mary BofinØystein StørkersenHelena BertilssonAlan J WrightGuro Fanneløb GiskeødegårdTone Frost BathenMorten Beck RyeMay-Britt TessemPublished in: NMR in biomedicine (2022)
Using an integrated approach, our study shows the potential of citrate and the dual upregulation of TOP2A and EZH2 as biomarkers for recurrence among radiotherapy patients.